Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Post-epidemic eosinophilia myalgia syndrome associated with L-Tryptophan

ABSTRACT: Eosinophilia–myalgia syndrome (EMS) is characterized by subacute onset of myalgias and peripheral eosinophilia, followed by chronic neuropathy and skin induration. The EMS epidemic in 1989 was linked to L-tryptophan consumption originating from a single source. Following the Food and Drug Administration (FDA) ban on the sale of L-tryptophan, the incidence of EMS declined rapidly. Moreover, no new cases have been published since the FDA ban was lifted in 2005. We report the clinical, histopathological and immunogenetic features of a new case of L-tryptophan-associated EMS along with evidence of activated transforming growth factor-ß and interleukin-4 signaling in the lesional skin.

ORGANISM(S): Homo sapiens

PROVIDER: GSE26934 | GEO | 2012/01/28

SECONDARY ACCESSION(S): PRJNA136089

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Post-epidemic eosinophilia myalgia syndrome associated with L-Tryptophan

Project description:Eosinophilia–myalgia syndrome (EMS) is characterized by subacute onset of myalgias and peripheral eosinophilia, followed by chronic neuropathy and skin induration. The EMS epidemic in 1989 was linked to L-tryptophan consumption originating from a single source. Following the Food and Drug Administration (FDA) ban on the sale of L-tryptophan, the incidence of EMS declined rapidly. Moreover, no new cases have been published since the FDA ban was lifted in 2005. We report the clinical, histopathological and immunogenetic features of a new case of L-tryptophan-associated EMS along with evidence of activated transforming growth factor-ß and interleukin-4 signaling in the lesional skin. 6 samples were analyzed to include EMS patient and two replicates along with three normal controls

2012-01-28 | E-GEOD-26934 | biostudies-arrayexpress

Homo sapiens

Project description:Post-epidemic eosinophilia myalgia syndrome associated with L-Tryptophan

| PRJNA136089 | ENA

Recurrent activating STAT5B N642H mutations in myeloid neoplasms with eosinophilia

Project description:Whole transcriptome sequencing (RNAseq) of 14 cases with suspected primary eosinophilia was performed to identify recurrent mutations which could be used as new diagnostic and prognostic markers as well as potential targets for therapy.

2019-01-12 | E-MTAB-7492 | biostudies-arrayexpress

Study of the impact of Anti-IL5 neutralizing antibodies on bone marrow eosinophil maturation stages during IL-33 induced eosinophilia.

Project description:RNA-seq of the 4 eosinophil maturation stages in the murine bone marrow during Interleukin-33 induced eosinophilia combined with Anti-IL5 or Control isotype injections.

2024-05-21 | GSE248712 | GEO

RNA-seq of the 4 stages of maturation of eosinophils in the murine bone marrow in the steady state and in Interleukin-33- induced eosinophilia.

Project description:Study of the transcriptional changes occurring during eosinophil maturation in the steady state and in IL-33 induced eosinophilia.

2024-05-21 | GSE229824 | GEO

RNA sequencing data from patients with drug reaction with eosinophilia and systemic symptoms to antibiotics

Project description:Drug reaction with eosinophilia and systemic symptoms (DRESS) is a cutaneous drug hypersensitivity reaction (DHR) with internal organ involvement and associated mortality, often caused by antibiotics. Despite the risk of severe systemic involvement, no robust diagnostic test to identify causative drug exists. To identify potential biomarkers, we evaluated changes in gene expression following exposure of PBMCs to a culprit antibiotic (cefoxitin, teicoplanin, vancomycin, dapsone) and developed a molecular assay test (MAT).

2023-05-03 | GSE160369 | GEO

Post-epidemic eosinophilia-myalgia syndrome associated with L-tryptophan.

Project description:Eosinophilia-myalgia syndrome (EMS) is characterized by subacute onset of myalgias and peripheral eosinophilia, followed by chronic neuropathy and skin induration. An epidemic of EMS in 1989 was linked to consumption of L-tryptophan that had originated from a single source. Following the ban by the Food and Drug Administration (FDA) on the sale of L-tryptophan, the incidence of EMS declined rapidly. Moreover, no new cases have been described since the FDA ban was lifted in 2005. We report the clinical, histopathologic, and immunogenetic features of a new case of L-tryptophan-associated EMS, along with evidence of activated transforming growth factor β and interleukin-4 signaling in the lesional skin.

| S-EPMC3848710 | biostudies-literature

Recurrent activating STAT5B N642H mutations in myeloid neoplasms with eosinophilia

Project description:Recurrent activating STAT5B N642H mutations in myeloid neoplasms with eosinophilia

| PRJEB30454 | ENA

Tissue Eosinophilia is Effective for Studying Differential Expression of Genes by RNA sequencing, and may offer Superior Insights into Chronic Rhinosinusitis than Study by Polyp Status

Project description:RNA sequencing (RNAseq) is being used to study inflammatory pathways in chronic rhinosinusitis (CRS). Our goal was to probe validity of tissue eosinophilia as a metric to study RNAseq in CRS. The study was conducted on prospectively enrolled subjects undergoing sinonasal surgery. Subjects were categorized as control, CRS, CRS with nasal polyps (CRSwNP) and CRS without nasal polyps (CRSsNP). CRS was also categorized by tissue eosinophil levels per high power field (EOS/HPF) as <10 EOS/HPF or ≥10 EOS/HPF. Ethmoidal tissue samples were processed, differentially expressed (DE) genes were calculated and Ingenuity pathway analysis (IPA) performed.Controls separated clearly from CRS by both study criteria (polyp status, EOS/HPF). In both analyses, CRS differentiated into two distinct CRS subgroups. However, heatmaps showed greater homogeneity within each CRS subtype when studied by eosinophilia versus polyp status. Overall, high differential gene expression was found in CRS versus controls, with 736 statistically significant differentially expressed (DE) genes. On comparison between between CRSwNP and CRSsNP, 60 DE genes were found and on analyzing by tissue EOS/HPF, 110DE genes were statistically significant between CRS <10 EOS/HPF and CRS ≥10 EOS/HPF analyses. Tissue eosinophilia as a metric was further validated by finding of IL 17 signalling pathway between <10EOS/HPF (increased) versus ≥10 EOS/HPF samples on pathway analysis. As a metric, tissue eosinophilia is at least as effective as analysis by polyp status for RNA sequencing and may potentially offer superior insights into mechanistic pathways.

2022-03-21 | GSE198950 | GEO

CCL11/CCR3-dependent eosinophilia alleviates malignant pleural effusions and improves prognosis

Project description:CCL11/CCR3-dependent eosinophilia alleviates malignant pleural effusions and improves prognosis

| PRJNA1029009 | ENA